Anti-rejection medicines after heart transplant
Treatments studied
Part of Heart & circulation clinical trials.
This study looks at using two anti-rejection medicines (everolimus and a lower dose of a calcineurin inhibitor) after a heart transplant. The goal is to see if this combination is safe and effective for keeping your body from rejecting the new heart, while possibly protecting your kidneys compared to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years old or older.
- Your heart transplant was at least 28 days ago and no more than 100 days ago (about 1–3 months ago).
- Your doctor thinks a combination of two anti-rejection drugs (everolimus and a calcineurin inhibitor) is right for you.
- You have not had another organ transplant before, and your heart transplant was not done with another organ.
- Your donated heart came from a donor who was younger than 70, and the donor's blood type was compatible with yours.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new approach to managing anti-rejection medicines after a heart transplant. It uses special blood tests to see if your immune system is calm, so doctors can safely reduce the medicines and lower side effects.
This study tests a drug called belatacept, which may help prevent the body from rejecting a new heart. It is given after a heart transplant, and the goal is to see if it works as well as or better than standard anti-rejection medicines.
This study tests antiplatelet medicines (like aspirin or clopidogrel) in people who have had a heart transplant. The goal is to see if these medicines can safely help prevent blood-related complications after transplant.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
This trial tests whether switching from a standard anti-rejection medicine to a different one (everolimus) about a year after a liver transplant can help protect your new liver with fewer side effects. If you qualify, you will be monitored closely for a few years to see how well the new medicine works for you.
This study tests whether continuing certain anti-rejection medicines while on dialysis can help lower the risk of your immune system becoming too sensitive to a future kidney transplant. It might help you stay eligible for another transplant later.
Hear when a new Heart Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.